SAI Life Sciences (SAILIFE) — 25 Aug 2026
Agent Adda offline research report for SAI Life Sciences (SAILIFE): business, financials, technical setup, and evidence trail.
Historical Showcase — Educational Content Only
This is a historical record of AI-generated technical analysis from 25 Aug 2026. The AI model identified these setups based on market data available at that time. All prices and setups shown have already played out — this is not actionable trading guidance. Published here to illustrate how the AgentAdda AI analysis pipeline works.
SAI Life Sciences (SAILIFE) — Research Summary (25 Aug 2026)
What it is
- Integrated CRDMO (CRO + CDMO); outcomes depend more on execution (quality/regulatory, capacity ramp, talent) than one-quarter noise.
FY26 snapshot (₹ Cr)
- Revenue: 2,192
- PAT: 349
Latest quarter context (Jun 2026, YoY)
- Revenue: 554 Cr (+11.7%)
- Operating profit: 148 Cr (+22.3%)
- PAT: 73 Cr (+21.7%)
Technical snapshot (as-of 2026-08-17)
- Stage 2, RSI 59.8, ADX 32.0
Decision frame (research-only)
- Bias: prefer adds on constructive consolidation; avoid chasing extended candles.
- Key watchpoints: FY27 capex/capability ramp + utilisation, margin bridge (mix/operating leverage), customer mix (large pharma vs biotech), audit/quality updates, hiring/attrition.
Invalidation / risk
- Repeated quality/compliance issues, or a sustained breakdown below key moving averages.
Freshness
- Data refreshed: 2026-08-25 (report is in offline cache mode; verify any “latest filings/news” items before sharing).
This report arrives by email before it's published here. Get the next one:
Full AI Analysis Report
This report is best viewed on a larger screen.
Open Full Report